Search Results for “aging” – Page 100 – media

Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer at 2017 ASCO Annual Meeting -Pivotal Monotherapy Phase 2 Trial Initiation Planned for 2017-

Astellas and Seattle Genetics, Inc. (NASDAQ: SGEN) highlighted updated phase 1 data for enfortumab vedotin (ASG-22ME) studied as monotherapy treatment for metastatic urothelial cancer (mUC) in an oral presentation at the American Society of Clinical Oncology (ASCO) 52nd Annual Meeting in Chicago. Enfortumab vedotin is an investigational antibody-drug conjugate (ADC) that targets Nectin-4, a cell surface protein expressed in multiple solid tumors including mUC, ovarian cancer, and non-small cell lung cancer (NSCLC). Based on the data from the ongoing phase 1 clinical trial, the companies this year plan to initiate a registrational monotherapy phase 2 trial for locally advanced or mUC patients who have been previously treated with checkpoint inhibitor (CPI) therapy. A trial evaluating enfortumab vedotin in combination with CPIs is also planned for later this year as part of a broad clinical development program.
- Source: newsroom.astellas.us
- 546
- March 28, 2018
Astellas monotherapy mUC Seattle Genetics
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) were published in the peer-reviewed journal The Lancet.
- Source: Novartis
- 537
- March 26, 2018
Clinical Trials SPMS
Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round

SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners.
- Source: BusinessWire
- 447
- March 26, 2018
Company Insights funding medical device products ostomy
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing

TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today the completion of an oversubscribed Series B financing of $125 million.
- Source: tcr2
- 499
- March 23, 2018
blood cancer Market Views solid tumor TCR
Tooth Sensor Measures Intake of Sugar, Salt, Alcohol

Having an accurate record of food and alcohol intake is important for managing a number of diseases including diabetes, various cardiovascular conditions, and alcoholism. Currently, not much practical technology is available to do this aside from smartphone apps, and apps tend to be tedious and require constant vigilance of making sure to input all the data.
- Source: Med Gadget
- 1,319
- March 23, 2018
diabetes digital health Researches
Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases

Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced a global collaboration with Celgene Corporation (CELG) through a subsidiary, to develop new therapies for a broad range of neurodegenerative diseases.
- Source: finance.yahoo
- 474
- March 22, 2018
Market Views neurodegenerative preclinical
Artificial intelligence firm twoXAR raises $10M for partnering drive

Artificial intelligence company twoXAR—a specialist in separating signals from noise in data-rich drug discovery projects—has raised $10 million in a first-round financing led by SoftBank Ventures.
- Source: Fiercebiotech
- 574
- March 22, 2018
diabetes financing Market Views
New wearable brain scanner allows patients to move freely for the first time

A new generation of brain scanner, that can be worn like a helmet allowing patients to move naturally whilst being scanned, has been developed by researchers at the Sir Peter Mansfield Imaging Centre, University of Nottingham and the Wellcome Centre for Human Neuroimaging, UCL. It is part of a five-year Wellcome funded project which has the potential to revolutionize the world of human brain imaging.
- Source: Medical Xpress
- 558
- March 22, 2018
brain medtech Researches
Insilico Medicine to launch R&D center and announce new research results in Taiwan ROC

Tuesday, March 20th, 2018, Insilico Medicine, a Baltimore-based artificial intelligence company specializing in drug discovery, biomarker development and aging research announced the launch of Insilico Taiwan, a subsidiary focusing on the development and validation of generative adversarial networks(GANs) and reinforcement learning for medicinal chemistry applications.
- Source: EurekAlert
- 582
- March 21, 2018
AI biomarker Company Insight Researches
UNITY Biotechnology, Inc. Completes $55 Million Series C Financing

UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, announced the closing of a $55 million Series C financing.
- Source: prnewswire
- 697
- March 21, 2018
aging Market Views Series

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.